Adamas Pharmaceuticals
13F holders, Q3 2024 (September 30)1holders −1
0new positions
1sold out
$0.00avg. 13F price*
At the end of Q3 2024, 1 institutions reported holding Adamas Pharmaceuticals in their 13F filings, down 1 from Q2 2024. 0 opened new positions and 1 sold out. The largest holder was MAI Capital Management ($0).
- Company
- Adamas Pharmaceuticals
- CUSIP
- 005CVR022
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 117,000 shares sold, net −117,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| MAI Capital Management | 0.00% | No change | 549,557 | $0 |
"% of holder's portfolio" is Adamas Pharmaceuticals's weight in each manager's 13F, not the share of Adamas Pharmaceuticals the manager owns.